Printer Friendly

WILLIAM M. WARDELL, M.D., PH.D., APPOINTED PRESIDENT OF PROTEIN ENGINEERING CORP.

 CAMBRIDGE, Mass., Jan. 4 /PRNewswire/ -- Protein Engineering Corporation (PEC) today announced that William M. Wardell, M.D., Ph.D., has been named president of the company. Dr. Wardell joins PEC from the Parke-Davis Pharmaceutical Research Division of Warner Lambert Company where he was most recently senior vice president, pharmaceutical research and healthcare. Dr. Wardell's 22 year career in new drug development combines senior management positions in the pharmaceutical industry with clinical pharmacology, medicine and academic research.
 "Bill has significant expertise in the areas of pharmacology, clinical trials and regulatory affairs, new drug development activities that will be important as PEC's protein-based therapies move into clinical development," commented John H. Freeman, chairman and chief executive officer of Protein Engineering Corp. "Bill will establish the strategic direction of PEC's drug development programs and will have a key role in our efforts to forge alliances with major pharmaceutical and biotechnology companies. We are pleased to welcome him as a member of our senior management team."
 From 1983 to 1991, Dr. Wardell was vice president-medical director at Boehringer Ingelheim Pharmaceuticals Inc., of Ridgefield, Conn., where he directed all U.S. medical functions including clinical research and regulatory affairs. From 1971 to 1983, Dr. Wardell was on the faculty of the University of Rochester Medical Center and Strong Memorial Hospital in Rochester, N.Y., in the Departments of Medicine and Pharmacology. He served in the Clinical Pharmacology Division, most recently as Associate Professor of pharmacology and medicine. Dr. Wardell was also a co-founder and director for seven years of the University's Center for Study of Drug Development which is now at Tufts University.
 Dr. Wardell has published over 100 scientific papers and three books on topics including clinical pharmacology, clinical trial methodology, and drug development and regulation. He holds a Ph.D. in pharmacology and an M.D. from Oxford University in England, and was a Merck International Fellow in clinical pharmacology.
 Protein Engineering Corporation was founded in 1987 to develop powerful, proprietary technology to engineer patentable proteins for use as therapeutic and diagnostic pharmaceuticals. Company headquarters are located in Cambridge, Mass.
 -0- 1/4/93
 /CONTACT: John H. Freeman of Protein Engineering Corporation, 617-868-0868; or Lynne H. Brum of Feinstein Partners Inc., 617-577-8110 for Protein Engineering Corporation/


CO: Protein Engineering Corporation ST: Massachusetts IN: MTC SU:

DD -- NE012 -- 1375 01/04/93 14:50 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 4, 1993
Words:391
Previous Article:SIMPLEX TO RECEIVE $500 MILLION AWARD FOR UNDERSEA CABLE FROM AT&T
Next Article:NORTHEAST BANCORP STOCK PURCHASER FILES SUIT
Topics:


Related Articles
PROTEIN ENGINEERING CORP. ANNOUNCES U.S. PATENT AWARDED ON METHODS TO GENERATE TARGETED DNA-BINDING PROTEINS
CELL GENESYS ANNOUNCES KEY PRODUCT DEVELOPMENT HIRES
CELL GENESYS ADDS TWO KEY PRODUCT DEVELOPMENT DIRECTORS
STRESSGEN AWARDED FEDERAL R & D GRANT AIMED AT STRESS PROTEIN-BASED THERAPEUTICS
First Round of Life Sciences Corridor Funds Awarded, Reports Michigan Economic Development Corporation.
Protein Polymer Technologies Announces Election of Board of Directors.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters